Robot model
Fitbit (Charge / Sense / Versa)
Fitbit, founded in 2007 by James Park and Eric Friedman and acquired by Google in a roughly $2.1 billion deal that closed in January 2021, is now a Google product line rather than an independent company, and its devices are biometric-primary fitness bands and watches with atrial-fibrillation AI augmentation. Its current and last-generation devices include the Charge 6 from 2023, the Sense 2, and the Versa 4, carrying optical heart-rate sensing, ECG electrodes on the Sense line, a continuous electrodermal stress sensor on the Sense 2, blood oxygen, and skin temperature, plus Sleep Score, Sleep Profile, a Daily Readiness Score, and stress management. Its FDA clearances are the ECG app, cleared in September 2020 for on-demand assessment of atrial fibrillation versus sinus rhythm, and passive PPG-based Irregular Heart Rhythm Notifications, cleared on April 11, 2022 across a broad device range. Its blood oxygen, electrodermal stress, Sleep Score, and Daily Readiness features are wellness-grade and not FDA-cleared for any diagnostic claim. On current state, while standalone Fitbit-branded smartwatch hardware has been deprioritized with no Sense 3 and the smartwatch strategy consolidated onto the Pixel Watch, Google confirmed in October 2025 that new Fitbit hardware, expected to be trackers, is coming in 2026 along with a Fitbit Coach AI feature, so the line is deprioritized rather than dead. Its clinical-validation posture is the strongest in the cohort specifically on atrial fibrillation, anchored by the large prospective Fitbit Heart Study, while the 2026 Fitbit hardware specifications and the Fitbit Coach AI capabilities are unannounced and not verified.
Fitbit (Charge / Sense / Versa) is a biometric robot built by
Machine-readable surfaces
- Markdown mirror: /models/fitbit-tracker.md
- JSON-LD: embedded in this page’s head
- REST API: /v1/models/fab68c69-1024-4aa2-8528-243454922840
- Data documentation: /data
- Form factor
- biometric
- Maturity stage
- commercial
- Lifecycle
- active
- Deployments
- 0
- ID
fab68c69-1024-4aa2-8528-243454922840
Specs
- notes
- [object Object],[object Object],[object Object],[object Object]
- specs
- Fitbit (Charge 6 (2023), Sense 2, Versa 4 - current/last-gen). Sensors: optical HR/PPG, ECG electrodes (Sense/Sense 2), cEDA stress sensor (Sense 2), SpO2, skin temperature. AI/health: AFib/ECG, Sleep Score + Sleep Profile, Daily Readiness Score, stress management. Founded 2007 (James Park + Eric Friedman); acquired by Google, closed Jan 2021 (~$2.1B). Hardware purchase + optional Fitbit Premium (~$9.99/mo).
- formFactor
- biometric (biometric-primary fitness band/watch + AI augmentation; AFib/ECG cleared)
Supply chain
No verified supply relationships on file. Supply-chain coverage is being added across the registry; check back as the seed populates this model’s suppliers.
Suppliers appear here when verified with at least two strong sources (maker-official / IR / regulatory / standards-body / verified tier-2). Sources are append-only; corrections add new sources rather than rewrite history.
Sources (3)
Common questions
- What is Fitbit (Charge / Sense / Versa)?
- Fitbit, founded in 2007 by James Park and Eric Friedman and acquired by Google in a roughly $2.1 billion deal that closed in January 2021, is now a Google product line rather than an independent company, and its devices are biometric-primary fitness bands and watches with atrial-fibrillation AI augmentation. Its current and last-generation devices include the Charge 6 from 2023, the Sense 2, and the Versa 4, carrying optical heart-rate sensing, ECG electrodes on the Sense line, a continuous electrodermal stress sensor on the Sense 2, blood oxygen, and skin temperature, plus Sleep Score, Sleep Profile, a Daily Readiness Score, and stress management. Its FDA clearances are the ECG app, cleared in September 2020 for on-demand assessment of atrial fibrillation versus sinus rhythm, and passive PPG-based Irregular Heart Rhythm Notifications, cleared on April 11, 2022 across a broad device range. Its blood oxygen, electrodermal stress, Sleep Score, and Daily Readiness features are wellness-grade and not FDA-cleared for any diagnostic claim. On current state, while standalone Fitbit-branded smartwatch hardware has been deprioritized with no Sense 3 and the smartwatch strategy consolidated onto the Pixel Watch, Google confirmed in October 2025 that new Fitbit hardware, expected to be trackers, is coming in 2026 along with a Fitbit Coach AI feature, so the line is deprioritized rather than dead. Its clinical-validation posture is the strongest in the cohort specifically on atrial fibrillation, anchored by the large prospective Fitbit Heart Study, while the 2026 Fitbit hardware specifications and the Fitbit Coach AI capabilities are unannounced and not verified.
- Who makes Fitbit (Charge / Sense / Versa)?
- Fitbit (Charge / Sense / Versa) is made by Fitbit, based in San Francisco, California, USA, founded in 2007.
- Where is Fitbit (Charge / Sense / Versa) deployed?
- No verified deployments of Fitbit (Charge / Sense / Versa) are currently on the DEPLOY registry. DEPLOY records deployments only when verified at a named site with a primary source; absence may reflect pre-deployment, research, or manufacturer-internal use.
- What is Fitbit (Charge / Sense / Versa)'s maturity stage?
- Fitbit (Charge / Sense / Versa) is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.